⚠️

Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.

Read our methodology →

Ihab ZiadaMD

Internal Medicine · Nashua, NH 3060

NPI: 1053407114

Share:

30

🟠 Elevated

🤖 ML Fraud Detection Score: 98%

Machine learning model identifies prescribing patterns consistent with confirmed fraud cases. This is a statistical indicator, not an accusation.

Learn more →

Risk Flags

High long-acting opioid rate vs peersHigh antipsychotic prescribing (65+)Opioid + benzodiazepine co-prescriber

Risk indicators are statistical patterns, not allegations. Learn more

10,532

Total Claims

$980K

Drug Cost

600

Beneficiaries

$1,633

Cost/Patient

Risk Score Breakdown 30/100

Low (0)Moderate (15)Elevated (30)High (50+)
Elderly antipsychotic prescribing+10
Long-acting opioid rate+8
Opioid + benzodiazepine combo+8

Score components are additive. Read full methodology

Peer Comparison vs. 110,156 Internal Medicine providers

+305%

Opioid rate vs peers

9.1% vs 2.2% avg

+16%

Cost per patient vs peers

$1,633 vs $1,411 avg

-4%

Brand preference vs peers

10.2% vs 10.6% avg

⚠️ Opioid + Benzodiazepine Co-Prescriber

This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.

🔎 Data Overview

🤖

Our machine learning model — trained on 281 confirmed fraud cases — gives this provider a "Very High" fraud-pattern score. All 20 decision trees in our ensemble model agree that this provider's prescribing patterns resemble those of confirmed fraud cases. This is a statistical finding, not an accusation.

💊

Opioid rate is 305% above Internal Medicine peers. This is a significant deviation that may reflect a specialized patient population or concerning prescribing patterns.

⚠️

This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.

Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.

Opioid Prescribing

9.1%

Opioid Rate

955

Opioid Claims

$98K

Opioid Cost

21.0%

Long-Acting Rate

Brand vs Generic

90% generic

Brand: 1,064 claims · $704K

Generic: 9,385 claims · $271K

Top Prescribed Drugs

Drug (Generic)ClaimsCost
Apixaban102$115K
Oxycodone Hcl49$71K
Sitagliptin Phosphate43$63K
Rivaroxaban58$52K
Dulaglutide19$35K
Semaglutide20$32K
Fluticasone/Vilanterol53$31K
Insulin Glargine,hum.Rec.Anlog39$25K
Empagliflozin17$21K
Tiotropium Bromide16$16K
Fluticasone/Umeclidin/Vilanter22$15K
Budesonide/Formoterol Fumarate15$11K
Oxycodone Hcl412$10K
Insulin Nph Hum/Reg Insulin Hm15$10K
Umeclidinium Brm/Vilanterol Tr14$9,164

Prescribing Profile

146

Unique Drugs

$252K

IRA Negotiated Drugs

$67K

GLP-1 Drugs

30.0

Anomaly Score

Patient Profile

70

Avg Age

54%

Female

1.27

Avg Risk Score

Explore More

Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About